KalVista's Sebetralstat Shows Consistent Efficacy for Hereditary Angioedema
• KalVista Pharmaceuticals presented data at the Bradykinin Symposium 2024, highlighting sebetralstat's consistent efficacy and safety in treating hereditary angioedema (HAE) attacks.
• Clinical trials showed sebetralstat provided rapid symptom relief, with a median time to relief of 1.8 hours for all attacks and 1.3 hours for laryngeal attacks.
• The oral administration of sebetralstat may offer advantages over current injectable treatments, potentially improving patient compliance and earlier treatment initiation.
• Sebetralstat demonstrated a safety profile comparable to placebo, reinforcing its potential as a transformative on-demand treatment for HAE.
© Copyright 2025. All Rights Reserved by MedPath